Liver Fibrosis/NASH/MASH Treatment Market Report 2025-2035

Regulatory challenges and market barriers in the approval of NASH/MASH treatment drugs.

NASH/MASH is a public health crisis that can lead to progressive liver fibrosis and cirrhosis. MASH is primarily associated with type 2 diabetes and cardiovascular diseases. Clinical trials need to demonstrate the ability of NASH treatments to slow disease progression and prevent onset by measuring composite endpoints related to liver-related outcomes. However, since there are currently no effective treatments for NASH, the U.S. FDA is providing an alternative approval pathway. This pathway relies on good clinical outcomes during trials, along with histopathological assessments of disease progression through liver biopsy as an alternative endpoint. Therefore, the U.S. FDA will approve drugs that meet the primary endpoint by demonstrating an improvement of more than one stage in fibrosis without worsening MASH or achieving resolution of MASH without worsening fibrosis. 【Contents】 ■ Market Overview ■ Market Analysis (by Drug Type, Clinical Pipeline, End User) ■ Regional Market Analysis ■ Company Profiles

others